search icon
Join IDSAJOIN IDSA >> Go to MyIDSAGO TO MYIDSA >>
  • Print
  • ShareThis
  • Text Size
  •  Policy Communications

  • Search More Policy
    09/04/2017

    IDSA & HIVMA Letter on NDAA

    Dear Senators McCain and Reed:
    We are writing on behalf of the Infectious Diseases Society of America (IDSA) and the HIV Medicine Association (HIVMA) to express our opposition to provisions in S. 1519, The National Defense Authorization Act for Fiscal Year 2018 that would impose severe restrictions on medical research funded through the Department of Defense (DoD) and impose onerous requirements on research grant recipients.
    08/29/2017

    IDSA Letter to new USAID Administrator

    Dear Administrator Green,
    The Infectious Diseases Society of America extends our congratulations on your confirmation as Administrator of the U.S. Agency for International Development.
    08/29/2017

    IDSA Letter to New WHO Director General

    Dear Dr. Tedros,
    The Infectious Diseases Society of America extends our congratulations on your election as Director General of the World Health Organization.
    07/21/2017

    IDSA Letter on Moscow TB Declaration

    Dear Intergovernmental Working Group,
    The Infectious Diseases Society of America commends your efforts to foster robust political support for ending the global tuberculosis epidemic by developing the draft Moscow Declaration for the WHO Global Ministerial Conference on Ending Tuberculosis in advance of the November meeting.
    07/06/2017

    Letter to Sec. Tillerson on Global HIV Funding

    Dear Secretary Tillerson,
    We, the undersigned members of the Global AIDS Policy Partnership (GAPP) and other concerned organizations in the US write today to express concern with both the funding levels and policy directions for global HIV/AIDS programs in the administration FY2018 budget for the State Department and in your testimony to State, Foreign Operations and Related Programs Appropriations sub-committees.
    05/30/2017

    GAPP Politico Ad

    Investments in the International Affairs budget are critical for the health and safety of families and
    communities around the world, like those affected by HIV/AIDS. We are at crossroads in the fight
    against AIDS: investments over the next four years are imperative if we are going to end the AIDS
    epidemic as a global health threat by 2030.
    05/15/2017

    Medical Societies write to Sec. Price on Fogarty

    Dear Secretary Price:
    We write as leaders of organizations strongly committed to the discovery mission of the National Institutes of Health and who believe that sustaining U.S. leadership in biomedical research is vital to domestic and global public health as well as American security and prosperity.
    01/31/2017

    Physicians ask Pres. Trump for robust global ID response

    Dear Mr. President:
    As physicians and scientists who have seen firsthand the value of U.S. leadership in global health, we are writing to share our insights on the impacts of the investments this country has made and the vital importance of continuing them.
    10/05/2016

    Letter to Amb. Birx on need for IPT Data

    Dear Ambassador Birx:
    As longtime supporters of PEPFAR, we have appreciated the role of the program in addressing TB-HIV comorbidity. As you know, TB is the single biggest killer of people living with HIV and the risk to this population of developing active TB continues to be high even following initiation of anti-retroviral therapy.
    06/01/2016

    Letter to Senate Leaders on Military Medical Research

    Dear Senators McCain and Reed:
    We are writing on behalf of the Infectious Diseases Society of America and the HIV Medicine Association to express our concerns with provisions in S. 2943, The National Defense Authorization Act for Fiscal Year 2017, which would impose severe restrictions on medical research funded through the Department of Defense and impose onerous audit and contracting requirements on research grant recipients.
    05/19/2016

    Letter on FDA Priority Review Voucher Program

    Dear Chairman Pitts and Ranking Member Green:
    We are writing to request that you support proposed changes to the Food and Drug Administration (FDA) Priority Review Voucher (PRV) program to ensure that it effectively accomplishes its goal of incentivizing new research and development (R&D) for neglected diseases, and that new neglected diseases products brought to market through the PRV program are made accessible and affordable to those who need them.

| HIVMA | Contact Us

© Copyright IDSA 2017 Infectious Diseases Society of America

Full Site Mobile Site